An observational study in Abdominal Neoplasm, sponsored by Xiangdong Cheng. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-26.
Sponsored by Xiangdong Cheng · Observational
Abdominal noncontrast scan and contrast-enhanced CT were used to establish a screening and diagnostic model for abdominal tumors
Secondary objective: To establish a grading model of abdominal tumors based on clinical indicators Exploratory Objective: To include CT scans in large-scale non-tumor populations for validation and to improve model accuracy Certainty
67 studies on the registry are indexed under Abdominal Neoplasms; 18 are open to participants now.
This study's planned enrollment of 100,000 is above the median of 100 across 15 observational studies indexed under Abdominal Neoplasms.
Browse Abdominal Neoplasms studies →Xiangdong Cheng is the lead sponsor of 6 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with abdominal tumors or Non-tumor population
Exclusion Criteria:
Whether or not there is a diagnosis of abdominal tumor questionnaire
Whether or not there is a diagnosis of abdominal tumor
Time frame: first visited at baseline
Plan to share: Yes — Abdominal noncontrast scan and contrast-enhanced CT were used to establish a screening and diagnostic model for abdominal tumors
Supporting information: Study protocol
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Xiangdong Cheng